Argentina Argentina Belize Belize Brasil Brasil Canada (English) Canada (English) Canada (Français) Canada (Français) Chile Chile Colombia Colombia Costa Rica Costa Rica Curaçao Curaçao El Salvador El Salvador Ecuador Ecuador Guatemala Guatemala Guyana Guyana Honduras Honduras Jamaica Jamaica México México Nicaragua Nicaragua Panamá Panamá Perú Perú Puerto Rico Puerto Rico República Dominicana República Dominicana Suriname Suriname Venezuela Venezuela United States (English) United States (English) België België Bosna i Hercegovina Bosna i Hercegovina Česko Česko Danmark Danmark Deutschland Deutschland Eesti Eesti España España France France Hrvatska Hrvatska Ireland Ireland Ísland Ísland Italia Italia Latvija Latvija Lietuva Lietuva Magyarország Magyarország Malta Malta Nederland Nederland Norge Norge Polska Polska Portugal Portugal România România Schweiz (Deutsch) Schweiz (Deutsch) Suisse (Français) Suisse (Français) Slovenija Slovenija Slovensko Slovensko Srbija Srbija Suomi Suomi Sverige Sverige Türkiye Türkiye United Kingdom United Kingdom Österreich Österreich Ελλάδα Ελλάδα България България Македонија Македонија Россия Россия Україна Україна South-Africa South-Africa ישראל ישראל الأردن الأردن الإمارات العربية المتحدة الإمارات العربية المتحدة البحرين البحرين المملكة العربية السعودية المملكة العربية السعودية ایران ایران پاکستان پاکستان عُمان عُمان قطر قطر لبنان لبنان مصر مصر العراق العراق الكويت الكويت Australia Australia Hong Kong SAR Hong Kong SAR 中国香港 中国香港 India India Indonesia Indonesia Malaysia Malaysia New Zealand New Zealand Philippines Philippines Singapore Singapore Việt Nam Việt Nam ไทย ไทย 대한민국 대한민국 中国 中国 中国台湾 中国台湾 日本 日本
Argentina Argentina Belize Belize Brasil Brasil Canada (English) Canada (English) Canada (Français) Canada (Français) Chile Chile Colombia Colombia Costa Rica Costa Rica Curaçao Curaçao El Salvador El Salvador Ecuador Ecuador Guatemala Guatemala Guyana Guyana Honduras Honduras Jamaica Jamaica México México Nicaragua Nicaragua Panamá Panamá Perú Perú Puerto Rico Puerto Rico República Dominicana República Dominicana Suriname Suriname Venezuela Venezuela United States (English) United States (English) België België Bosna i Hercegovina Bosna i Hercegovina Česko Česko Danmark Danmark Deutschland Deutschland Eesti Eesti España España France France Hrvatska Hrvatska Ireland Ireland Ísland Ísland Italia Italia Latvija Latvija Lietuva Lietuva Magyarország Magyarország Malta Malta Nederland Nederland Norge Norge Polska Polska Portugal Portugal România România Schweiz (Deutsch) Schweiz (Deutsch) Suisse (Français) Suisse (Français) Slovenija Slovenija Slovensko Slovensko Srbija Srbija Suomi Suomi Sverige Sverige Türkiye Türkiye United Kingdom United Kingdom Österreich Österreich Ελλάδα Ελλάδα България България Македонија Македонија Россия Россия Україна Україна South-Africa South-Africa ישראל ישראל الأردن الأردن الإمارات العربية المتحدة الإمارات العربية المتحدة البحرين البحرين المملكة العربية السعودية المملكة العربية السعودية ایران ایران پاکستان پاکستان عُمان عُمان قطر قطر لبنان لبنان مصر مصر العراق العراق الكويت الكويت Australia Australia Hong Kong SAR Hong Kong SAR 中国香港 中国香港 India India Indonesia Indonesia Malaysia Malaysia New Zealand New Zealand Philippines Philippines Singapore Singapore Việt Nam Việt Nam ไทย ไทย 대한민국 대한민국 中国 中国 中国台湾 中国台湾 日本 日本

Convatec’s Advanced Wound Care innovation leads the industry at European Wound Management Association (EWMA) 2026

  • Convatec will showcase new clinical and real world evidence across next generation foam technology, nitric oxide generating dressings, and Wound Hygiene
  • Convatec-sponsored scientific symposia to spotlight patient-centred innovation supported by robust in-vitro and clinical data enabling HCPs to deliver better outcomes
  • Convatec to unveil Aquacel™ ConvaFiber™ in its European debut ahead of scale-up later this year

London, UK, 5 May 2026 – Convatec, a leading medical products and technology company focused on solutions for the management of chronic conditions, takes to the stage showcase the breadth, depth and momentum behind its Advanced Wound Care innovation pipeline at the European Wound Management Association (EWMA) 2026 conference in Bremen, Germany, from 6–8 May 2026.

Convatec’s industry-leading Advanced Wound Care innovation is supported by compelling new data from randomised controlled trials (RCTs) and real-world studies, with 13 abstracts accepted for publication and presentation at EWMA evaluating outcomes in hard-to-heal wounds across foam, multimodal, nitric oxide-generating dressings, antimicrobial technology and Wound Hygiene.

Convatec has launched or secured approvals for five new wound care products since 2023, demonstrating our commitment to pioneering innovative solutions to support patients and healthcare professionals, including:

  • ConvaFoam™: Best-in-class multi-layer foam dressing designed to be repositionable on application to avoid wasted dressing changes¹. ConvaFoam™ is the only foam dressing that combines three technologies – Aquacel® Hydrofiber®, superabsorber fibers and ConvaTac™ silicone – to deliver superior exudate management2 with skin friendly adhesion for longer lasting wear time*¹.

  • ConvaNiox™: A transformative solution³, shaping a new category in the management of hard-to-heal wounds by combining an advanced dressing technology with a powerful antimicrobial and antibiofilm agent, nitric oxide. ConvaNiox™’s multimodal technology³, MultiFusion™, supports the healing of 60% more diabetic foot ulcers (DFUs), with 3x faster wound area reduction compared to standard-of-care dressings⁴.

  • Aquacel™ ConvaFiber™: Next-generation, soft, sterile and conformable⁵ primary dressing with advanced Hydrofiber® technology resulting in 45% more absorbency⁶ (vs Aquacel® Extra™), designed to manage a broad range of acute and chronic wounds⁷.

  • ConvaMatrix™: Recently approved innovative, single use wound matrix - a unique porcine placental-derived technology designed to support the body's natural healing response in DFUs and venous leg ulcers (VLUs). It combines the structural benefits of the placenta⁸˒⁹ with the reproducibility and safety profile of a medical device¹⁰⁻¹².

  • ConvaVAC™: First and only Negative Pressure Wound Therapy (NPWT) system partnered with Aquacel® Hydrofiber® technology utilising a bacterial sequestration and autolytic debridement wound contact layer to control the bioburden whilst delivering NPWT to promote wound healing**¹³⁻¹⁷.

This year’s EWMA programme also marks 30 years of Hydrofiber® technology, Convatec’s proprietary wound care platform that underpins the next generation of wound care innovation to help manage the burden of wound care. Almost 1.5 billion Aquacel® dressings have been sold worldwide leveraging the technology over the last three decades.

As part of the scientific programme at EWMA 2026, Convatec will host a series of symposia to explore emerging evidence from across its Advanced Wound Care portfolio and discuss what it means for real-world clinical practice, including:

6 May 2026 from 16:00 – 17:00: Introducing ConvaNiox™: multimodal, nitric oxide-generating dressing

The session, chaired by Professor José Luis Lázaro-Martínez, University of Madrid, will explore emerging laboratory and clinical evidence, highlighting ConvaNiox™’s multimodal approach to support healing in diabetic foot ulcers.

7 May 2026 from 16:16 – 17:15: A year of healing with ConvaFoam™: Advancing wound care with a next-generation foam dressing.

The session will focus on the published clinical data exploring ConvaFoam™’s mode of action in pressure injury prevention, including insights on complex cases from guest speaker Dr Przemyslaw Lipinski, ARGO Medical Centre.

Tanja Dormels, President, Advanced Wound Care at Convatec, said:“The challenges facing wound care require more than incremental change. At EWMA 2026, Convatec will demonstrate how our deep, diversified and evidence-led innovation pipeline will meaningfully advance healing and reshape clinical practice through Wound Hygiene. Underpinned by 30 years of Hydrofiber® technology, rigorous clinical evidence and Convatec’s strongest ever wound care pipeline, we are leading the industry in advanced wound care to meet the needs of patients and healthcare professionals worldwide.”

For more information on the programme of events, visit Convatec at EWMA 2026.

Scientific programme

 

Aquacel® Ag+ Extra™

 

ConvaNiox™

 

ConvaFoam™

 

ConvaMatrix™

 

Real world data

 

 
  • Versus selected dressings tested in vitro for absorption, retention, fluid handling and adhesion

**As demonstrated in vitro

Notes to Editor

Discover more about Convatec’s Advanced Wound Care portfolio at: Advanced Wound Care | Convatec

References

 

1. Adhesion Characteristics of ConvaFoam WHRI8050 MS172

2. WHRI9478 MS186_DHF1093 ConvaFoam Superiority Report – Testing between May 2021 - June 2022.

3. ConvaNiox Claims summary. RPT-088112 v3.0, 2026, Data on file, Convatec Inc.

4. Edmonds ME, et al. Multicenter, randomized controlled, observer-blinded study of a nitric oxide generating treatment in foot ulcers of patients with diabetes-ProNOx1 study. Wound Repair Regen. 2018;26(2):228-237.

5. WHRI10174 MS192 In-Vitro Performance Characteristics of Aquacel ConvaFiber Conformability, Data on file 2025, Convatec Inc

6. WHRI10176 MS194, In-Vitro Performance Characteristics of Aquacel ConvaFiber versus Aquacel Extra, Data on file 2025, Convatec Inc

7. Aqualcel™ ConvaFiber™ Instructions for use.

8. R. Islam, et al. Properties and Therapeutic Potential of Human Amniotic Membrane. Asian Journal of Dermatology. 2015; 7(1), 1-2.

9. N. Fairbairn, et al. The clinical applications of human amnion in plastic surgery. Journal of Plastic, Reconstructive & Aesthetic Surgery, 2014; 67(5), 662-675.

10. MDR 821626 Summary

11. Data on file -RDR-002

12. Badylak Memo-001

13. GR Newman et al (2006), Visualisation of bacterial sequestration and bactericidal activity within hydrating Hydrofiber® wound dressings, Biomaterials, 27(7): 1129-1139, ISSN 0142-9612.

14. PG Bowler et al (1999). Infection control properties of some wound dressings. J Wound Care, 8(10):499-502.

15. WHRI10863 MS207 ConvaVAC™ NPWT with Aquacel™ Hydrofiber® Technology

16. MJ Waring, D Parsons (2001), Physico-chemical characterisation of carboxymethylated spun cellulose fibres, Biomaterials, 22(9): 903-912.

17. M Walker et al (2003), Scanning electron microscopic examination of bacterial immobilisation in a carboxymethyl cellulose (AQUACEL®) and alginate dressings, Biomaterials, 24(5):883-890.

 

Contact

Media: MediaRelations@convatec.com
Investor relations: ir@convatec.com

About Convatec

Pioneering trusted medical solutions to improve the lives we touch: Convatec is a global medical products and technologies company, focused on solutions for the management of chronic conditions, with leading positions in Advanced Wound Care, Ostomy Care, Continence Care, and Infusion Care. With over 10,000 colleagues, we provide products and services in around 90 countries, united by a promise to be forever caring. Our solutions provide a range of benefits, from infection prevention, treatment for hard to heal wounds, at-risk skin and ulcerated tissue to supporting debilitating conditions, improved patient outcomes and reduced care costs. Convatec's revenues in 2025 were over $2 billion. The company is a constituent of the FTSE 100 Index (LSE:CTEC). To learn more please visit: http://www.convatecgroup.com.

Date of preparation: April 2026
AP-80142-GBL-ENG-v1

Press Release

See all

18-Nov-26

Corporate

Financial Performance

logo, company name

Trading update for the ten months ended 31 October 2026

Convatec announces trading update for the ten months ended 31 October 2026

Read more Read more

03-Nov-26

Corporate

Director updates

Director updates

Convatec announces Board changes

Read more Read more

03-Nov-26

Corporate

Chief Financial Officer succession

Chief Financial Officer succession

Jill McConnell appointed Chief Financial Officer (Designate), effective 1 January 2027.

Read more Read more

06-Oct-26

Corporate

Ostomy Care

Convatec survey challenges assumptions about leakage in ostomy care

Convatec survey challenges assumptions about leakage in ostomy care

New global findings highlight the role of peristomal skin health

Read more Read more

28-Sep-26

Corporate

Continence Care

Cure Aqua™ launches in the United States and Canada

Convatec expands Cure™ portfolio with launch of Cure Aqua™, bringing greater ...

Cure Aqua™ launches in the United States and Canada

Read more Read more

27-Aug-26

Corporate

Non-Executive Director appointment

Non-Executive Director appointment

Dr Jens Viebke appointed as a Non-Executive Director, effective immediately.

Read more Read more

14-Aug-26

Corporate

Our People

Convatec appoints Dave Ubachs as Chief Digital & Information Officer

Convatec appoints Dave Ubachs as Chief Digital & Information Officer

Convatec announces the appointment of Chief Digital & Information Officer

Read more Read more

04-Aug-26

Corporate

Convatec commences share buyback programme

Convatec commences share buyback programme

Convatec will commence a non-discretionary share buyback programme

Read more Read more

04-Aug-26

Corporate

Financial Performance

Interim results for the six months ended 30 June 2026

Interim results for the six months ended 30 June 2026

Convatec announces interim results for the six months ended 30 June 2026

Read more Read more

15-Jul-26

Corporate

Convatec today announces two Board changes

Chief Financial Officer succession and Non-Executive Director appointment

Convatec announces two Board changes

Read more Read more

03-Jul-26

Corporate

Advanced Wound Care

Convatec completes over £24 million expansion of UK manufacturing site, strengthening supply of advanced wound care solutions

Convatec completes over £24 million expansion of UK manufacturing site, stren...

Convatec announces the completion of a multi-year expansion of over £24 million at Rhymney manufacturing site

Read more Read more

09-Jun-26

Corporate

Communities

Convatec and Lilly Foundation commit $5m to Partners In Health to improve car...

Convatec's commitment represents the next phase of its collaboration with Partners In Health

Read more Read more

04-Jun-26

Corporate

Our People

Convatec announces leadership appointments to strengthen Science, Innovation, Quality and Regulatory Affairs

Convatec announces leadership appointments to strengthen Science, Innovation,...

Convatec announces executive leadership roles for Science & Innovation and Quality & Regulatory Affairs

Read more Read more

21-May-26

Corporate

Financial Performance

AGM trading update for the four months ended 30 April 2026

AGM trading update for the four months ended 30 April 2026

AGM trading update for the four months ended 30 April 2026

Read more Read more

05-May-26

Corporate

Advanced Wound Care

Convatec’s Advanced Wound Care innovation leads the industry at EWMA 2026

Convatec’s Advanced Wound Care innovation leads the industry at European Woun...

Convatec’s Advanced Wound Care innovation leads the industry at EWMA 2026

Read more Read more

21-Apr-26

Corporate

Our People

Convatec appoints Peter Jarvis as Chief Operations Officer

Convatec appoints Peter Jarvis as Chief Operations Officer

Convatec appoints Chief Operations Officer

Read more Read more